Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers

被引：23

作者：

Ammannagari, Nischala ^{[1
]}

Atasoy, Ajlan ^{[1
]}

机构：

[1] Roswell Pk Canc Inst, Dept Med, Elm & Carlton St, Buffalo, NY 14263 USA

来源：

JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2018年 / 9卷 / 01期

关键词：

PD-1; PD-L1; check point inhibition; gastroesophageal cancer; REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; INDEPENDENT PROGNOSTIC-FACTOR; PROGRAMMED DEATH-1 LIGAND-1; MISMATCH REPAIR DEFICIENCY; GASTRIC-CANCER; MICROSATELLITE INSTABILITY; OPEN-LABEL; SUPPRESSOR-CELLS; JUNCTION CANCER;

D O I：

10.21037/jgo.2017.06.12

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastroesophageal (GE) cancers continue to be a significant cause of mortality globally. Despite therapeutic advances in oncology, the prognosis of advanced GE cancer remains exceedingly poor. Immunotherapy has caused a major paradigm shift in the field of oncology. Not all patients benefit from these agents and several studies are trying to identify predictive and prognostic biomarkers to better inform and guide treatment decisions. The potential role of immunotherapy in GE cancers is emerging. These cancer types are molecularly and immunologically heterogeneous, and this heterogeneity influences the tumor microenvironment posing a significant challenge to studying biomarkers of response to immunotherapy. Here in this article, we discuss the need for new therapeutic approaches in GE cancers, review the emerging data on the activity of checkpoint inhibitors and the role of biomarkers in this setting.

引用

页码：196 / 207

页数：12

共 74 条

[41] Helicobacter pylori Infection Causes Characteristic DNA Damage Patterns in Human Cells [J].

Koeppel, Max ;

Garcia-Alcalde, Fernando ;

Glowinski, Frithjof ;

Schlaermann, Philipp ;

Meyer, Thomas F. .

CELL REPORTS, 2015, 11 (11) :1703-1713

[42] CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers [J].

Kono, Koji ;

Kawaida, Hiromichi ;

Takahashi, Akihiro ;

Sugai, Hidemitsu ;

Mimura, Kosaku ;

Miyagawa, Naoto ;

Omata, Hideo ;

Fujii, Hideki .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (09) :1064-1071

[43] Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial [J].

Kudo, Toshihiro ;

Hamamoto, Yasuo ;

Kato, Ken ;

Ura, Takashi ;

Kojima, Takashi ;

Tsushima, Takahiro ;

Hironaka, Shuichi ;

Hara, Hiroki ;

Satoh, Taroh ;

Iwasa, Satoru ;

Muro, Kei ;

Yasui, Hirofumi ;

Minashi, Keiko ;

Yamaguchi, Kensei ;

Ohtsu, Atsushi ;

Doki, Yuichiro ;

Kitagawa, Yuko .

LANCET ONCOLOGY, 2017, 18 (05) :631-639

[44] Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer [J].

Lee, H. E. ;

Chae, S. W. ;

Lee, Y. J. ;

Kim, M. A. ;

Lee, H. S. ;

Lee, B. L. ;

Kim, W. H. .

BRITISH JOURNAL OF CANCER, 2008, 99 (10) :1704-1711

[45] Clinical Impact of Tumor-Infiltrating Lymphocytes for Survival in Stage II Colon Cancer [J].

Lee, Won-Suk ;

Park, Sanghui ;

Lee, Woo Yong ;

Yun, Seong Hyeon ;

Chun, Ho-Kyung .

CANCER, 2010, 116 (22) :5188-5199

[46] Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas [J].

Lin, Suling J. ;

Gagnon-Bartsch, Johann A. ;

Tan, Iain Beehuat ;

Earle, Sophie ;

Ruff, Louise ;

Pettinger, Katherine ;

Ylstra, Bauke ;

van Grieken, Nicole ;

Rha, Sun Young ;

Chung, Hyun Cheol ;

Lee, Ju-Seog ;

Cheong, Jae Ho ;

Noh, Sung Hoon ;

Aoyama, Toru ;

Miyagi, Yohei ;

Tsuburaya, Akira ;

Yoshikawa, Takaki ;

Ajani, Jaffer A. ;

Boussioutas, Alex ;

Yeoh, Khay Guan ;

Yong, Wei Peng ;

So, Jimmy ;

Lee, Jeeyun ;

Kang, Won Ki ;

Kim, Sung ;

Kameda, Yoichi ;

Arai, Tomio ;

zur Hausen, Axel ;

Speed, Terence P. ;

Grabsch, Heike I. ;

Tan, Patrick .

GUT, 2015, 64 (11) :1721-1731

[47] Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer [J].

Masuzawa, Toru ;

Fujiwara, Yoshiyuki ;

Okada, Kaoru ;

Nakamura, Ayumu ;

Takiguchi, Shuji ;

Nakajima, Kiyokazu ;

Miyata, Hiroshi ;

Yamasaki, Makoto ;

Kurokawa, Yukinori ;

Osawa, Ryuji ;

Takeda, Kazuyoshi ;

Yoshida, Koji ;

Tsunoda, Takuya ;

Nakamura, Yusuke ;

Mori, Masaki ;

Doki, Yuichiro .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (04) :1297-1304

[48] Early toxicity in a randomized trial of high dose-rate (HDR) brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. [J].

Morton, Gerard ;

Chung, Hans T. ;

McGuffin, Merrylee ;

Zhang, Liying ;

Ravi, Ananth ;

D'Alimonte, Laura ;

Loblaw, Andrew .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)

[49] Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial [J].

Muro, Kei ;

Chung, Hyun Cheol ;

Shankaran, Veena ;

Geva, Ravit ;

Catenacci, Daniel ;

Gupta, Shilpa ;

Eder, Joseph Paul ;

Golan, Talia ;

Le, Dung T. ;

Burtness, Barbara ;

McRee, Autumn J. ;

Lin, Chia-Chi ;

Pathiraja, Kumudu ;

Lunceford, Jared ;

Emancipator, Kenneth ;

Juco, Jonathan ;

Koshiji, Minori ;

Bang, Yung-Jue .

LANCET ONCOLOGY, 2016, 17 (06) :717-726

[50] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer [J].

Ohigashi, Y ;

Sho, M ;

Yamada, Y ;

Tsurui, Y ;

Hamada, K ;

Ikeda, N ;

Mizuno, T ;

Yoriki, R ;

Kashizuka, H ;

Yane, K ;

Tsushima, F ;

Otsuki, N ;

Yagita, H ;

Azuma, M ;

Nakajima, Y .

CLINICAL CANCER RESEARCH, 2005, 11 (08) :2947-2953

← 1 2 3 4 5 6 7 8 →